B. Kahl

J. Vose, M. Horowitz, R. Negrin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

M. Czuczman, J. Leonard, B. Cheson, 2009, Cancer.

Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study

KyungMann Kim, H. Bailey, E. Williams, 2005, Cancer investigation.

Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma

S. Howard, B. Flynn, J. Eickhoff, 2005, Leukemia & lymphoma.

Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.

I. Flinn, Y. Oki, S. Horwitz, 2013 .

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

R. Ulrich, J. Byrd, I. Flinn, 2010 .

Initial treatment of elderly population with aggressive lymphoma: a narrative review of current evidence and future directions

B. Kahl, Behzad Amoozgar, 2022, Annals of Lymphoma.

Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.

J. Byrd, I. Flinn, T. Jahn, 2013 .

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

D. Scott, Sonali M. Smith, J. Friedberg, 2019, Blood.

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

C. Flowers, K. Blum, N. Ghosh, 2021, Blood advances.

Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab

T. Kourelis, B. Kahl, P. Benn, 2011, Acta Haematologica.

Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP

B. Hill, B. Kahl, 2022, Expert review of hematology.

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.

K. Ardeshna, C. Carlo-Stella, P. Caimi, 2020, Blood advances.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma

J. Friedberg, J. Leonard, M. Leblanc, 2017, Journal of the National Cancer Institute.

A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)

R. Advani, R. Gascoyne, L. Gordon, 2010 .

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

R. Advani, R. Gascoyne, L. Gordon, 2016 .

A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial

R. Gascoyne, D. Scott, L. Gordon, 2011 .

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

E. Kimby, B. Cheson, P. Zinzani, 2015, Leukemia & lymphoma.

Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.

B. Kahl, J. Cohen, 2020, Hematology/oncology clinics of North America.

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

R. Gascoyne, J. Krauss, S. Horning, 2011 .

What Is the Best Initial Therapy for a Patient With Symptomatic Low-Grade Follicular Lymphoma?

B. Kahl, V. Kenkre, 2012, Cancer journal.

Integrating emerging treatment options in mantle cell lymphoma: introduction.

B. Kahl, 2013, Clinical advances in hematology & oncology : H&O.

Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

J. Byrd, I. Flinn, Jennifer R. Brown, 2010 .

Acute promyelocytic leukaemia and acquired α‐2‐plasmin inhibitor deficiency: a retrospective look at the use of epsilon‐aminocaproic acid (Amicar) in 30 patients

D. Mosher, T. Wassenaar, B. Schwartz, 2008, Hematological oncology.

ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP

D. Scott, J. Friedberg, T. Habermann, 2019, Hematological Oncology.

Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496)

R. Gascoyne, L. Gordon, T. Habermann, 2016, Cancer.

Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies

Sonali M. Smith, C. Nabhan, B. Kahl, 2012, Leukemia and Lymphoma.

Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

J. Friedberg, B. Cheson, L. Tremmel, 2010, Clinical lymphoma, myeloma & leukemia.

Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia.

C. Erlichman, M. Gertz, S. Geyer, 2005, Clinical lymphoma.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Sonali M. Smith, J. Friedberg, J. Winter, 2019, Leukemia & lymphoma.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

G. Salles, I. Flinn, C. Flowers, 2017, Haematologica.

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

J. Manola, R. Advani, T. Habermann, 2012, Leukemia & lymphoma.

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

L. Staudt, W. Wilson, S. Steinberg, 2014 .

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

L. Staudt, W. Chan, W. Wilson, 2022, Blood.

An iatrogenic orphan?

B. Kahl, 2019, Blood.

Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.

B. Kahl, D. Guy, Daniel G. Guy, 2020, Hematology/oncology clinics of North America.

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

R. Advani, R. Gascoyne, L. Gordon, 2017, Leukemia.

MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

J. Vose, K. Savage, D. Neuberg, 2005 .

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)

S. Ansell, M. Robertson, S. Barta, 2019, Hematological Oncology.

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

R. Advani, S. Ansell, F. Hong, 2018, Blood.

Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)

R. Advani, S. Ansell, F. Hong, 2015 .

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

S. Treon, Z. Hunter, L. Ioakimidis, 2011, Blood.

Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?

B. Kahl, 2019, The Hematologist.

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Sonali M. Smith, J. Friedberg, J. Leonard, 2017 .

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL

R. Gascoyne, D. Scott, J. Friedberg, 2017 .

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

W. Choi, J. Winter, M. Piris, 2012, Blood.

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

K. Dybkær, G. Bhagat, Y. Zu, 2014, Leukemia.

Bulky aggressive B-cell lymphoma: to radiate or not to radiate--that is the question.

B. Kahl, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Sonali M. Smith, A. LaCasce, J. Friedberg, 2018, Blood.

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Jeffrey A Jones, I. Flinn, Y. Oki, 2018, Blood.

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

R. Ulrich, J. Byrd, I. Flinn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Cancer.

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma

B. Hill, J. Kaiser, Anson Snow, 2022, Leukemia & lymphoma.

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

I. Lossos, J. Castillo, B. Hess, 2020, Blood.

Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).

B. Kahl, 2006, Clinical lymphoma & myeloma.

Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma

I. Flinn, S. Horwitz, H. Stern, 2014 .

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

J. Byrd, I. Flinn, B. Smith, 2009 .

Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival

C. Flowers, K. Blum, J. Switchenko, 2021, European journal of haematology.

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

R. Advani, S. Ansell, F. Hong, 2016 .

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

J. Leonard, S. de Vos, R. Fisher, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies

Michael L. Wang, J. Goldberg, M. Dreyling, 2017, British journal of haematology.

Bendamustine: more ammunition in the battle against mantle cell lymphoma

B. Kahl, Julie E. Chang, 2012, Leukemia & lymphoma.

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

Y. Natkunam, R. Advani, R. Gascoyne, 2014, Leukemia & lymphoma.

Current treatment approaches in follicular lymphoma.

B. Kahl, 2015, Clinical advances in hematology & oncology : H&O.

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2015 .

NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells

Michael L. Wang, Fang Wang, S. Safe, 2017, Blood Cancer Journal.

LOTIS 2 FOLLOW-UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Infectious Mononucleosis Progressing to Fatal Malignant Lymphoma: A Case Report and Review of the Literature

B. Kahl, D. Norback, C. Kobbervig, 2003, Leukemia & lymphoma.

Bendamustine for treatment of chronic lymphocytic leukemia

B. Kahl, Julie E. Chang, 2012, Expert opinion on pharmacotherapy.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael L. Wang, R. Advani, K. Blum, 2012 .

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

R. Advani, R. Gascoyne, S. Horning, 2012 .

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Michael L. Wang, R. Advani, W. Jędrzejczak, 2013, The New England journal of medicine.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

G. Salles, I. Flinn, C. Flowers, 2014, The New England journal of medicine.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

W. Wilson, S. Steinberg, A. LaCasce, 2018, The Lancet. Haematology.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

T. Kipps, A. Roberts, M. Davids, 2016, The New England journal of medicine.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

R. Advani, R. Gascoyne, D. Scott, 2012, Blood.

Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop

R. Gascoyne, L. Gordon, M. Dreyling, 2015, Leukemia & lymphoma.

High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma

W. C. Chan, R. Gascoyne, B. Sander, 2014, Oncogene.

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

R. Gascoyne, S. Horning, J. Kolesar, 2013, Journal of Hematology & Oncology.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

J. Byrd, T. Kipps, M. Dwyer, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

R. Ulrich, J. Byrd, I. Flinn, 2014, Blood.

Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

Joshua F. McMichael, Zachary L. Skidmore, Christopher A. Miller, 2021, medRxiv.

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

Erica K. Barnell, Zachary L. Skidmore, R. Fulton, 2022, medRxiv.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy

Eneida A. Mendonça, Amy K. Erbe, A. Naranjo, 2017, Front. Immunol..

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

T. Kipps, A. Roberts, M. Davids, 2015 .

Microscale functional cytomics for studying hematologic cancers.

David J Beebe, Edmond W K Young, D. Beebe, 2012, Blood.

Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells

KyungMann Kim, N. Callander, S. Miyamoto, 2008, Molecular Cancer Research.

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

KyungMann Kim, H. Bailey, B. Kahl, 2008, Leukemia & lymphoma.

B-cell lymphoma patients treated with R-CHOP : report from an Mutational profile and prognostic significance of TP 53 in diffuse large

W. Choi, J. Winter, K. Dybkær, 2012 .

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Tuan S. Nguyen, N. Schmitz, Sonali M. Smith, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2013, Haematologica.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

J. Vose, A. LaCasce, S. de Vos, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K. Dybkær, W. Tam, G. Bhagat, 2012, Leukemia.

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

T. Miller, T. Kipps, A. Roberts, 2013 .

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).

R. Advani, R. Gascoyne, L. Gordon, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop

W. Wilson, R. Gascoyne, J. Connors, 2011, Leukemia & lymphoma.

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study

I. Flinn, Y. Oki, S. Horwitz, 2018, American journal of hematology.

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

J. Byrd, I. Flinn, Jennifer R. Brown, 2014, Blood.

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

Sonali M. Smith, J. Friedberg, J. Leonard, 2017, British journal of haematology.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

R. Advani, R. Gascoyne, L. Gordon, 2013, British journal of haematology.

Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations

J. Connors, J. Friedberg, J. Leonard, 2017, Journal of the National Cancer Institute.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

Targeting BCL-2 in Hematologic Malignancies

B. Kahl, N. Khan, 2018, Targeted Oncology.

FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

S. Miyamoto, L. Rui, J. Eickhoff, 2016, Oncogene.

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

D. Scott, J. Friedberg, J. Leonard, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.

J. Radford, P. Zinzani, K. Ardeshna, 2021, The Lancet. Oncology.

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

R. Advani, A. Roberts, S. Enschede, 2015, British journal of haematology.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Michael L. Wang, R. Advani, W. Jędrzejczak, 2015, Blood.

INDOLENT B-CELL LYMPHOMA Follicular lymphoma : evolving therapeutic strategies

David T Yang, B. Kahl, 2016 .

The Role of rituximab for newly diagnosed, refractory or relapsed aggressive B‐cell lymphoma in adult patients

C. Fitzmaurice, B. Kahl, Bradley Heraly, 2016 .

Follicular lymphoma: Management options in the era of targeted therapy

B. Kahl, C. Peterson, 2005, Current treatment options in oncology.

Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.

J. Sacco, L. Trepanier, B. Kahl, 2011, British journal of clinical pharmacology.

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

C. Jones, J. Zehnder, J. Eickhoff, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Amit Verma, Adrian Wiestner, Samir Parekh, 2010, Blood.

Augmented and standard Berlin–Frankfurt–Münster chemotherapy for treatment of adult acute lymphoblastic leukemia

KyungMann Kim, E. Esterberg, J. Lionberger, 2008, Leukemia & lymphoma.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

W. Wilson, S. Steinberg, P. Bierman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study

J. Radford, K. Ardeshna, O. O’Connor, 2018, Blood.

Current Status of Targeted Therapies for Mantle Cell Lymphoma

B. Kahl, Julie E. Chang, 2011, Drugs.

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

K. Young, S. Miyamoto, S. Markovina, 2008, Molecular Cancer.

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

P. Ganly, S. Opat, C. Tam, 2020, Haematologica.

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

L. Staudt, A. Rosenwald, W. Chan, 2006, Blood.

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

L. Staudt, A. Rosenwald, W. Chan, 2006, Blood.

T‐Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

J. Friedberg, J. Leonard, S. Horwitz, 2017, Journal of the National Cancer Institute.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Marginal zone lymphomas: management of nodal, splenic, and MALT NHL.

B. Kahl, David Yang, 2008, Hematology. American Society of Hematology. Education Program.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era

R. Gascoyne, D. Scott, T. Witzig, 2018, Blood Cancer Journal.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

A. Rosenwald, R. Gascoyne, N. Schmitz, 2018, Blood.

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

M. Berger, A. Goy, B. Kahl, 2014, Leukemia & lymphoma.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

A. Evens, E. Petersdorf, H. Lazarus, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predictors of Indolent Versus Aggressive Disease Behavior for Patients With Newly Diagnosed Mantle Cell Lymphoma

J. Zain, B. Kahl, Jonathon B. Cohen, 2017 .

Follicular lymphoma: evolving therapeutic strategies.

David T Yang, B. Kahl, 2016, Blood.

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 )

R. Advani, R. Gascoyne, S. Horning, 2014 .

Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.

J. Eickhoff, A. Traynor, B. Kahl, 2014, Clinical advances in hematology & oncology : H&O.

Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).

R. Gascoyne, S. Horning, Michael E. Williams, 2007 .

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

J. Eickhoff, H. Bailey, B. Kahl, 2011, Leukemia & lymphoma.

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

W. Wilson, L. Sehn, Sonali M. Smith, 2016, Journal of the National Cancer Institute.

Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

R. Advani, R. Gascoyne, L. Gordon, 2007 .

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

I. Lossos, J. Friedberg, P. Zinzani, 2022, Blood advances.

Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era

C. Fletcher, B. Kahl, 2014, Leukemia & lymphoma.

Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop

L. Gordon, L. Quintanilla‐Martinez, M. Dreyling, 2017, Leukemia & lymphoma.

Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop

L. Gordon, P. Jares, T. Witzig, 2014, Leukemia & lymphoma.

Evolving treatment strategies in mantle cell lymphoma.

B. Kahl, N. Edwin, 2018, Best practice & research. Clinical haematology.

Current and emerging treatment options for mantle cell lymphoma

B. Fakhri, B. Kahl, 2017, Therapeutic advances in hematology.

Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents

B. Kahl, 2009, Current hematologic malignancy reports.

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Yoonjin Cho, John P Leonard, R. Ulrich, 2014, Blood.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Sonali M. Smith, J. Friedberg, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop

L. Gordon, P. Jares, Michael E. Williams, 2013, Leukemia & lymphoma.

Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib

J. Byrd, I. Flinn, Y. Oki, 2014 .

a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

I. Flinn, Y. Oki, S. Horwitz, 2014 .

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

N. Wages, G. Petroni, Michael E. Williams, 2021, Blood advances.

The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

B. Kahl, V. Kenkre, 2012, Current Hematologic Malignancy Reports.

Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

I. Flinn, S. Horwitz, H. Stern, 2014 .

Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.

J. Friedberg, B. Cheson, B. Kahl, 2010, Clinical advances in hematology & oncology : H&O.

Is It Time for Time-limited Therapy in Frontline CLL?

B. Kahl, 2019, The Hematologist.

Frontline CLL Options: An Embarrassment of Riches?

B. Kahl, 2019 .

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

J. Byrd, T. Kipps, M. Dwyer, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

R. Advani, J. Winter, B. Cheson, 2008 .

Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).

T. Kipps, A. Roberts, M. Davids, 2016 .

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Patricia L. Harris, Y. Oki, S. Horwitz, 2013 .

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

T. Kipps, A. Roberts, M. Davids, 2014 .

The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients

A. Roberts, M. Davids, J. Pagel, 2013 .

Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era

C. Flowers, K. Blum, N. Ghosh, 2021, American journal of hematology.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

L. Staudt, W. Wilson, A. Zelenetz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Bruce D Cheson, R. Advani, J. Winter, 2014, Journal of Hematology & Oncology.

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2020 .

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts

G. Salles, B. Hill, Anita Kumar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

Moving Beyond CHO(E)P for Peripheral T-cell Lymphoma

N. Mehta-Shah, B. Kahl, 2021, The Hematologist.

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

O. Griffith, F. Gao, M. Griffith, 2021, Clinical Cancer Research.

Top advances in lymphoma for 2021

B. Kahl, D. Patel, 2022, Cancer.

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

T. Miller, T. Kipps, A. Roberts, 2013 .

Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079.

S. Treon, Z. Hunter, B. Kahl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma

J. Cerhan, R. Gascoyne, C. Copie-Bergman, 2016, American journal of hematology.

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

R. Advani, Sonali M. Smith, A. Tulpule, 2014 .

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2009 .

Follicular lymphoma: are we ready for a risk-adapted approach?

B. Kahl, 2017, Hematology. American Society of Hematology. Education Program.

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

R. Advani, R. Gascoyne, J. Winter, 2017 .

Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.

B. Kahl, 2018, Clinical advances in hematology & oncology : H&O.

P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN PATIENTS WITH TREATMENT-NAÏVE (TN) CLL/SLL

C. Tam, P. Ghia, B. Kahl, 2022, HemaSphere.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Profound imbalance of pro-fibrinolytic and anti-fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation

D. Mosher, B. Schwartz, B. Kahl, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Sonali M. Smith, P. Venugopal, S. Singer, 2023, Leukemia & lymphoma.

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study

A. Onitilo, Kyungeun Kim, Sandeep Saha, 2015, Cancer.

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies.

Eric C Frey, George Sgouros, Yong Du, 2009, Medical physics.

Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

J. Radford, K. Ardeshna, O. O’Connor, 2020, Blood.

Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?

B. Kahl, D. Landsburg, 2019, Clinical lymphoma, myeloma & leukemia.

Non-Hodgkin lymphoma

G. Nowakowski, David T Yang, B. Kahl, 2016 .

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis

S. Kanters, B. Kahl, G. Ball, 2021, BMC Cancer.

SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412)

R. Ambinder, B. Kahl, C. Diefenbach, 2017 .

General Biomarker Recommendations for Lymphoma.

L. Staudt, K. Fu, R. Gascoyne, 2016, Journal of the National Cancer Institute.

Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.

P. Riedell, T. Fehniger, K. Carson, 2016, Journal of the National Cancer Institute.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

J. Burke, J. Briones, P. Abrisqueta, 2021, The Lancet. Haematology.

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

I. Lossos, J. Cerhan, J. Friedberg, 2022, Blood advances.

OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY

C. Flowers, K. Blum, P. Martin, 2019, Hematological Oncology.

Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2013 .

Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

I. Flinn, K. Allison, S. Horwitz, 2013 .

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation

B. Kahl, M. Nazeef, 2015, Current Treatment Options in Oncology.

Mantle cell lymphoma-management in evolution.

B. Kahl, S. Rajguru, Saurabh A. Rajguru, 2014, Chinese clinical oncology.

Emerging therapy for the treatment of mantle cell lymphoma.

B. Kahl, S. Rajguru, Saurabh A. Rajguru, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.

R. Advani, R. Gascoyne, S. Horning, 2009 .

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

N. Callander, J. Eickhoff, B. Kahl, 2008 .

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

R. Advani, K. Blum, Michael E. Williams, 2011 .

The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study

W. Choi, J. Winter, K. Dybkær, 2011 .

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma , Version 2 . 2019 CE

J. Byrd, T. Kipps, A. Chanan-Khan, 2019 .

A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial

N. Schmitz, Sonali M. Smith, K. Savage, 2013 .

Long-term safety experience with bendamustine for injection in a real-world setting

A. Pathak, P. Barr, L. James, 2016, Expert opinion on drug safety.

Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

R. Gascoyne, T. Habermann, J. Krauss, 2016, British journal of haematology.

Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era

R. Advani, R. Gascoyne, L. Gordon, 2015, British journal of haematology.

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

J. Radford, K. Ardeshna, A. Stathis, 2022, Blood advances.

Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure

L. Medeiros, Shaoying Li, A. Behdad, 2020, Cancer.

Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Sonali M. Smith, J. Friedberg, J. Winter, 2016, British journal of haematology.

Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma

R. Advani, S. Ansell, K. Dorritie, 2023, American journal of hematology.

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

R. Advani, R. Gascoyne, L. Gordon, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402

R. Advani, R. Gascoyne, S. Horning, 2015, British journal of haematology.

Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

J. Friedberg, J. Leonard, B. Cheson, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

R. Advani, R. Gascoyne, T. Habermann, 2015, British journal of haematology.

Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?

B. Kahl, 2019, The Hematologist.

Integrating emerging treatment options in mantle cell lymphoma.

M. Czuczman, N. Fowler, B. Kahl, 2013, Clinical advances in hematology & oncology : H&O.

Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

I. Flinn, R. Wahl, E. Frey, 2004 .

Analysis of Peripheral T‐cell Lymphoma Diagnostic Workup in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Clinical lymphoma, myeloma & leukemia.

Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)

G. Nowakowski, N. Wagner-Johnston, B. Kahl, 2021, Blood.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

R. Advani, R. Gascoyne, D. Scott, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R

W. Wilson, J. Friedberg, K. Dunleavy, 2017 .

SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma.

B. Kahl, D. Patel, 2023, Clinical lymphoma, myeloma & leukemia.

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

K. Trinkaus, N. Bartlett, T. Fehniger, 2023, Clinical lymphoma, myeloma & leukemia.

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

R. Advani, R. Gascoyne, T. Habermann, 2012 .

ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, K. Ardeshna, 2021 .

Update: gastric MALT lymphoma

B. Kahl, 2003, Current opinion in oncology.

Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant

C. Flowers, K. Blum, N. Ghosh, 2019, Blood.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with follicular non-hodgkins lymphoma (FL) beyond first complete response or first partial response

J. Vose, J. Klein, M. Horowitz, 2008 .

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

T. Habermann, S. Horning, S. Ansell, 2004, Journal of Clinical Oncology.

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

A. Roberts, M. Davids, J. Pagel, 2012 .

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

J. Friedberg, J. Leonard, S. Gore, 2021, Blood.

Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

R. Gascoyne, D. Scott, M. Czuczman, 2019, Blood.

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

J. Friedberg, J. Leonard, T. Witzig, 2019, Blood.

Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.

I. Lossos, J. Cerhan, J. Friedberg, 2018 .

Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.

J. Zain, B. Kahl, J. Cohen, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

A. Roberts, M. Davids, J. Pagel, 2014, Clinical advances in hematology & oncology : H&O.

Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.

M. Czuczman, J. Leonard, B. Cheson, 2007 .

Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.

R. Fisher, B. Djulbegovic, A. Boral, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

V. Seshan, P. Caimi, M. Okwali, 2022, Blood.

Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Advanced Hematologic Malignancies

I. Flinn, S. Horwitz, A. Younes, 2012 .

Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.

R. Advani, L. Gordon, J. Connors, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

J. Burke, K. Kolibaba, I. Flinn, 2017 .

Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers

I. Lossos, J. Cerhan, T. Habermann, 2017 .

CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

R. Advani, Sonali M. Smith, J. Chavez, 2020 .

Current Controversies in the Management of Hodgkin's Lymphoma

K. Bradley, B. Kahl, Julie E. Chang, 2007 .

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

R. Advani, R. Gascoyne, L. Gordon, 2011 .

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Scott E. Smith, L. Staudt, W. Wilson, 2016 .

Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

P. Riedell, B. Hess, B. Hill, 2020 .

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

I. Lossos, J. Cerhan, T. Habermann, 2018, Blood.

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

R. Advani, R. Gascoyne, T. Habermann, 2016 .

Current Treatments in Marginal Zone Lymphoma.

B. Kahl, J. Alderuccio, 2022, Oncology.

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Sonali M. Smith, P. Venugopal, S. Singer, 2023, American journal of hematology.

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

P. Stiff, K. Ruffner, B. Kahl, 2010 .

Use of Tissue Microarray and Automated Quantitative Analysis for Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma

K. Young, David T Yang, B. Kahl, 2011, Applied immunohistochemistry & molecular morphology : AIMM.

A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa

R. Gangnon, B. Kahl, M. Juckett, 2004, Bone Marrow Transplantation.

CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL).

R. Greil, I. Flinn, Lei Zhou, 2021, Clinical lymphoma, myeloma & leukemia.

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

E. Hoster, J. Gribben, L. Sehn, 2015 .

R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793

R. Fisher, B. Cheson, T. Habermann, 2010 .

Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

L. Staudt, A. Rosenwald, W. Chan, 2008 .

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Sonali M. Smith, J. Friedberg, J. Leonard, 2020 .

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

P. Riedell, N. Bartlett, T. Fehniger, 2019, Blood.

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.

R. Advani, Sonali M. Smith, J. Chavez, 2021, Blood.

Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).

Joshua T. Cohen, J. Raemaekers, J. Friedberg, 2020 .

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

P. Riedell, B. Hess, B. Hill, 2023, Blood advances.

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

J. Cerhan, J. Leonard, A. Feldman, 2022, Blood advances.

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2017 .

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Sonali M. Smith, J. Friedberg, J. Leonard, 2023, Journal of Clinical Oncology.

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

W. Wilson, J. Friedberg, J. Leonard, 2023, Cancer medicine.

Mantle cell lymphoma: Report of the 2009 Mantle Cell Lymphoma Consortium Workshop

W. Wilson, J. Leonard, O. O’Connor, 2010, Leukemia & lymphoma.

Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies

Michael L. Wang, J. Goldberg, B. Liu, 2016 .

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

F. Morschhauser, K. Ardeshna, K. Izutsu, 2023, Hematological Oncology.

LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

J. Radford, K. Ardeshna, A. Stathis, 2023, Hematological Oncology.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.

J. Radford, K. Ardeshna, A. Stathis, 2023, Haematologica.

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, A. Stathis, 2019, Blood.

Synergistic Co-Targeting of BTK and BCL2 in Mantle Cell Lymphoma

L. Rui, S. Miyamoto, M. Bouchlaka, 2015 .

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood.

Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.

J. Zain, B. Kahl, Jonathon B. Cohen, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B)

J. Byrd, J. Leonard, I. Flinn, 2011 .

Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

C. Tam, Jennifer R. Brown, T. Robak, 2018 .

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A. Zelenetz, J. Leonard, I. Flinn, 2013 .

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

P. Westervelt, J. Dipersio, N. Bartlett, 2020 .

Clinical Trials and Observations

L. Staudt, A. Rosenwald, W. Chan, 2007 .

Structural profiles of TP 53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma : an international collaborative study

L. Staudt, A. Rosenwald, W. Chan, 2008 .